{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:47:17Z","timestamp":1790819237468,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Toxicology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.reprotox.2022.12.003","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T11:28:42Z","timestamp":1671449322000},"page":"124-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Pregnancy outcomes following maternal macrolide use: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"115","author":[{"given":"Elif","family":"Keskin-Arslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal","family":"Erol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusret","family":"Uysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Karadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tijen","family":"Temiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf Cem","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reprotox.2022.12.003_bib1","series-title":"Goodman Gilman\u2019s Pharmacol. Basis Ther","first-page":"1521","article-title":"Protein synthesis inhibitors and miscellaneous antibacterial agents","author":"Conan","year":"2011"},{"key":"10.1016\/j.reprotox.2022.12.003_bib2","first-page":"639","article-title":"Common bacterial and viral infections: review of management in the pregnant patient","volume":"53","author":"Rac","year":"2019","journal-title":"Ann. Pharm."},{"key":"10.1016\/j.reprotox.2022.12.003_bib3","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski","year":"2015","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.reprotox.2022.12.003_bib4","unstructured":"Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2014. Atlanta: U.S. Department of Health and Human Services; 2015. https:\/\/www.cdc.gov\/std\/stats\/archive\/surv-2014-print.PDF (accessed January 30, 2020)."},{"key":"10.1016\/j.reprotox.2022.12.003_bib5","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1471-0528.2000.tb13339.x","article-title":"The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin","volume":"107","author":"Heikkinen","year":"2000","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib6","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1067\/mob.2003.171","article-title":"Placental passage of clarithromycin surpasses other macrolide antibiotics","volume":"188","author":"Witt","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib7","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04286.x","article-title":"Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway","volume":"74","author":"Rom\u00f8ren","year":"2012","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.reprotox.2022.12.003_bib8","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1128\/AAC.01691-12","article-title":"Fetal safety of macrolides","volume":"57","author":"Dinur","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.reprotox.2022.12.003_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1055\/s-2007-994053","article-title":"A prospective controlled multicentre study of clarithromycin in pregnancy","volume":"15","author":"Einarson","year":"1998","journal-title":"Am. J. Perinatol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/14767050500439657","article-title":"Fetal outcome following roxithromycin exposure in early pregnancy","volume":"19","author":"Chun","year":"2006","journal-title":"J. Matern Neonatal Med."},{"key":"10.1016\/j.reprotox.2022.12.003_bib11","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/pds.3900","article-title":"Use of macrolides during pregnancy and the risk of birth defects: a population-based study","volume":"24","author":"B\u00e9rard","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"648","key":"10.1016\/j.reprotox.2022.12.003_bib12","article-title":"In utero exposure to antibiotics and risk of congenital malformations: a population-based study","volume":"221","author":"Damkier","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejogrb.2008.07.008","article-title":"Pregnancy outcome after gestational exposure to the new macrolides: a prospective multi-center observational study","volume":"141","author":"Bar-Oz","year":"2008","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2165\/11630920-000000000-00000","article-title":"The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study","volume":"35","author":"Bar-Oz","year":"2012","journal-title":"Drug Saf."},{"key":"10.1016\/j.reprotox.2022.12.003_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2393-6-18","article-title":"Pregnancy outcome following gestational exposure to azithromycin","volume":"6","author":"Sarkar","year":"2006","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.reprotox.2022.12.003_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-3016.2008.00978.x","article-title":"Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations","volume":"23","author":"Cooper","year":"2009","journal-title":"Paediatr. Perinat. Epidemiol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053327","article-title":"Clarithromycin in early pregnancy and the risk of miscarriage and malformation: a register based nationwide cohort study","volume":"8","author":"Andersen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.reprotox.2022.12.003_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0890-6238(03)00012-1","article-title":"Maternal drug use in early pregnancy and infant cardiovascular defect","volume":"17","author":"K\u00e4ll\u00e9n","year":"2003","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib19","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1111\/bcp.13364","article-title":"Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study","volume":"83","author":"Muanda","year":"2017","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.reprotox.2022.12.003_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.reprotox.2005.01.010","article-title":"Is erythromycin therapy teratogenic in humans","volume":"20","author":"K\u00e4ll\u00e9n","year":"2005","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00228-013-1624-3","article-title":"Fetal safety of erythromycin. An update of Swedish data","volume":"70","author":"K\u00e4ll\u00e9n","year":"2014","journal-title":"Eur. J. Clin. Pharm."},{"key":"10.1016\/j.reprotox.2022.12.003_bib22","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archpediatrics.2009.188","article-title":"Antibacterial medication use during pregnancy and risk of birth defects","volume":"163","author":"Crider","year":"2009","journal-title":"Arch. Pedia Adolesc. Med."},{"key":"10.1016\/j.reprotox.2022.12.003_bib23","doi-asserted-by":"crossref","first-page":"E625","DOI":"10.1503\/cmaj.161020","article-title":"Use of antibiotics during pregnancy and risk of spontaneous abortion","volume":"189","author":"Muanda","year":"2017","journal-title":"CMAJ"},{"key":"10.1016\/j.reprotox.2022.12.003_bib24","first-page":"366","article-title":"The fetal safety of macrolides: a meta-analysis of malformation risks following exposure in pregnancy","volume":"97","author":"Nordeng","year":"2013","journal-title":"Birth Defects Res Part A"},{"key":"10.1016\/j.reprotox.2022.12.003_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212212","article-title":"Associations between use of macrolide antibiotics during pregnancy and adverse child outcomes: a systematic review and meta-analysis","volume":"14","author":"Fan","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.reprotox.2022.12.003_bib26","article-title":"Prenatal exposure to macrolides and risk of congenital malformations: a meta-analysis","author":"Mallah","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.reprotox.2022.12.003_bib27","first-page":"1","article-title":"Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study","volume":"368","author":"Fan","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.reprotox.2022.12.003_bib28","doi-asserted-by":"crossref","first-page":"n107","DOI":"10.1136\/bmj.n107","article-title":"Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study","author":"Andersson","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.reprotox.2022.12.003_bib29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.reprotox.2021.01.006","article-title":"Macrolide and lincosamide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: a European case-control study","volume":"100","author":"Leke","year":"2021","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.reprotox.2022.12.003_bib31","first-page":"5","article-title":"Rayyan \u2014 a web and mobile app for systematic reviews","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.reprotox.2022.12.003_bib32","unstructured":"Wells G., Shea B., O\u2019Connell D., Peterson J., Welch V., Losos M., et al. The Newcastle-ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses n.d. \u3008http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp\u3009 (accessed March 3, 2020)."},{"key":"10.1016\/j.reprotox.2022.12.003_bib33","unstructured":"European Surveillance of Congenital Anomalies. Guide 1.4 Chapter 3.3. 2013 EUROCAT Subgroups of Congenital Anomalies ( Version 2014; implemented in EDMP December 2014, used for website prevalence tables from December 2014). EUROCAT 2013. https:\/\/eu-rd-platform.jrc.ec.europa.eu\/sites\/default\/files\/EUROCAT-Guide-1.4-Section-3.3.pdf (accessed January 31, 2020)."},{"key":"10.1016\/j.reprotox.2022.12.003_bib34","unstructured":"Deeks J.J., Higgins J.P.T., Altman D.G. (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. www.training.cochrane.org\/handbook. (accessed December 1, 2022)."},{"key":"10.1016\/j.reprotox.2022.12.003_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/pds.538","article-title":"Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations","volume":"9","author":"Drinkard","year":"2000","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.reprotox.2022.12.003_bib36","first-page":"484","article-title":"Pregnancy outcome after gestational exposure to the new macrolides: a prospective controlled cohort study","volume":"20","author":"Tellem","year":"2005","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib37","first-page":"477","article-title":"Does roxithromycin affect embryo development?","volume":"20","author":"Paulus","year":"2005","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib38","first-page":"6","article-title":"Antibiotics potentially used in response to bioterrorism and major congenital malformations","volume":"15","author":"Cooper","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.reprotox.2022.12.003_bib39","first-page":"85","article-title":"Maternal use of erythromycin and risk of congenital malformations: a population-based cohort study","volume":"15","author":"Wogelius","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.reprotox.2022.12.003_bib40","first-page":"229","article-title":"Maternal use of erythromycin and risk of congenital malformation and infantile hypertrophic pyloric stenosis: a danish population-based cohort study","volume":"17","author":"Rookkapan","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.reprotox.2022.12.003_bib41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.reprotox.2010.05.034","article-title":"Safety of macrolides during pregnancy\u2014with special focus on erythromycin and congenital heart malformations","volume":"30","author":"Nordeng","year":"2010","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib42","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/pds.2179","article-title":"Maternal use of antibiotics and the risk of orofacial clefts: a nationwide cohort study","volume":"21","author":"Molgaard-Nielsen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.reprotox.2022.12.003_bib43","doi-asserted-by":"crossref","first-page":"g1908","DOI":"10.1136\/bmj.g1908","article-title":"Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study","volume":"348","author":"Lund","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.reprotox.2022.12.003_bib44","first-page":"25","article-title":"Teratogenic risk of macrolides during the first trimester of pregnancy: a study with two complementary approaches within the EFEMERIS database","volume":"31","author":"Le Nguyen","year":"2017","journal-title":"Fundam. Clin. Pharm."},{"key":"10.1016\/j.reprotox.2022.12.003_bib45","first-page":"234","article-title":"A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin","volume":"79","author":"Czeizel","year":"2000","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.reprotox.2022.12.003_bib46","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.reprotox.2008.05.024","article-title":"Maternal drug use in early pregnancy and risk ofcardiovascular defect in infant\u2014a follow-up study","volume":"26","author":"Kallen","year":"2008","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib47","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0890-6238(99)00046-5","article-title":"A population-based case-control teratologic study of oral erythromycin treatment during pregnancy","volume":"13","author":"Czeizel","year":"1999","journal-title":"Reprod. Toxicol."},{"issue":"221","key":"10.1016\/j.reprotox.2022.12.003_bib48","article-title":"Safety of macrolides during pregnancy","volume":"208","author":"Lin","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00404-020-05569-4","article-title":"Association of antibiotics therapy during pregnancy with spontaneous miscarriage: a systematic review and meta-analysis","volume":"302","author":"Omranipoor","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.reprotox.2022.12.003_bib50","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1067\/mpd.2001.117577","article-title":"Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis","volume":"139","author":"Mahon","year":"2001","journal-title":"J. Pedia"},{"key":"10.1016\/j.reprotox.2022.12.003_bib51","unstructured":"European Surveillance of Congenital Anomalies. Guide 1.4, Section 3.2. Minor Anomalies for Exclusion. EUROCAT 2014. https:\/\/eu-rd-platform.jrc.ec.europa.eu\/sites\/default\/files\/Section 3.2- 27_Oct2016.pdf (accessed January 30, 2020)."},{"key":"10.1016\/j.reprotox.2022.12.003_bib52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/bdrb.21107","article-title":"Effects of macrolide antibiotics on rat embryonic heart function in vitro","volume":"101","author":"Nilsson","year":"2014","journal-title":"Birth Defects Res. Part B"},{"key":"10.1016\/j.reprotox.2022.12.003_bib53","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2174\/1381612013397744","article-title":"Class III antiarrhythmics and phenytoin: teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage","volume":"7","author":"Danielsson","year":"2001","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.reprotox.2022.12.003_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1027309703313","article-title":"Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel","volume":"254","author":"Stanat","year":"2003","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.reprotox.2022.12.003_bib55","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa040582","article-title":"Oral erythromycin and the risk of sudden death from cardiac causes","volume":"351","author":"Ray","year":"2004","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.reprotox.2022.12.003_bib56","unstructured":"REPROTOX. Agent Detail ERYTHROMYCIN STEARATE 2019. https:\/\/www.reprotox.org\/member\/agents\/17313 (accessed February 3, 2020)."},{"key":"10.1016\/j.reprotox.2022.12.003_bib57","unstructured":"Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) n.d. https:\/\/www.cdc.gov\/nchs\/icd\/icd9cm.htm (accessed February 5, 2020)."},{"key":"10.1016\/j.reprotox.2022.12.003_bib58","unstructured":"International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)-WHO Version for;2016 n.d. https:\/\/icd.who.int\/browse10\/2016\/en (accessed October 22, 2019)."},{"key":"10.1016\/j.reprotox.2022.12.003_bib59","unstructured":"DAILYMED. LABEL: BIAXIN- clarithromycin tablet, film coated BIAXIN- clarithromycin tablet, film coated, extended release BIAXIN- clarithromycin granule, for suspension. NIH 2012. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=2e899f4a-a2e9\u2013445c-a0ed-6ad811e997e6 (accessed January 6, 2020)."},{"key":"10.1016\/j.reprotox.2022.12.003_bib60","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1100\/tsw.2010.112","article-title":"Penile embryology and anatomy","volume":"10","author":"Yiee","year":"2010","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.reprotox.2022.12.003_bib61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1741-4520.2008.00189.x","article-title":"Specified critical period of different congenital abnormalities: a new approach for human teratological studies","volume":"48","author":"Czeizel","year":"2008","journal-title":"Congenit. Anom. (Kyoto)"},{"key":"10.1016\/j.reprotox.2022.12.003_bib62","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.diff.2012.06.003","article-title":"Molecular mechanisms of external genitalia development sarah","volume":"84","author":"Blaschko","year":"2012","journal-title":"Differentiation"},{"issue":"3","key":"10.1016\/j.reprotox.2022.12.003_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2014.09.028","article-title":"Immortal time bias in drug safety cohort studies: spontaneous abortion following nonsteroidal antiinflammatory drug exposure","volume":"212","author":"Daniel","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101123","article-title":"A Systematic Review and meta-analysis of the effect of administration of azithromycin during pregnancy on perinatal and neonatal outcomes","volume":"40","author":"Hume-Nixon","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.reprotox.2022.12.003_bib65","article-title":"Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling","author":"Committee For Medicinal Products For Human Use","year":"2008","journal-title":"Eur. Med. Agency Lond."},{"issue":"2","key":"10.1016\/j.reprotox.2022.12.003_bib66","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1213\/ANE.0000000000002741","article-title":"Significance, errors, power, and sample size: the blocking and tackling of statistics","volume":"126","author":"Mascha","year":"2018","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.reprotox.2022.12.003_bib67","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.clp.2005.04.006","article-title":"Maternal infection and adverse fetal and neonatal outcomes","volume":"32","author":"Goldenberg","year":"2005","journal-title":"Clin. Perinatol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib68","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/OLQ.0000000000000592","article-title":"Adverse birth outcomes and maternal Neisseria gonorrhoeae infection: a population-based cohort study in Washington State","volume":"44","author":"Heumann","year":"2017","journal-title":"Sex. Transm. Dis."},{"key":"10.1016\/j.reprotox.2022.12.003_bib69","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s10995-018-2451-z","article-title":"Chlamydia trachomatis and adverse pregnancy outcomes: meta-analysis of patients with and without infection","volume":"22","author":"Olson-Chen","year":"2018","journal-title":"Matern Child Health J."},{"key":"10.1016\/j.reprotox.2022.12.003_bib70","article-title":"A meta analysis on risks of adverse pregnancy outcomes in Toxoplasma gondii infection","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.reprotox.2022.12.003_bib71","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1479-828X.2001.tb01314.x","article-title":"A systematic review of pregnancy outcome following preterm premature rupture of membranes at a previable gestational age","volume":"41","author":"Dewan","year":"2001","journal-title":"Aust. N. Zeal J. Obstet. Gynaecol."},{"key":"10.1016\/j.reprotox.2022.12.003_bib72","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00431-018-3287-7","article-title":"Association between exposure to macrolides and the development of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis","volume":"178","author":"Abdellatif","year":"2019","journal-title":"Eur. J. Pedia"},{"key":"10.1016\/j.reprotox.2022.12.003_bib73","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00383-016-3971-5","article-title":"Post-natal erythromycin exposure and risk of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis","volume":"32","author":"Murchison","year":"2016","journal-title":"Pedia Surg. Int"}],"container-title":["Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623822001721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623822001721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:00:43Z","timestamp":1760191243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890623822001721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":73,"alternative-id":["S0890623822001721"],"URL":"https:\/\/doi.org\/10.1016\/j.reprotox.2022.12.003","relation":{},"ISSN":["0890-6238"],"issn-type":[{"value":"0890-6238","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pregnancy outcomes following maternal macrolide use: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Reproductive Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reprotox.2022.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}